Connect with us

TechCrunch

FindAir is a smart inhaler

FindAir is digitizing asthma therapy with smart inhaler technology. The TC Top Picks program showcases outstanding early-stage startups across these categories: AI/Machine Learning, Biotech/Healthtech, Blockchain, Fintech, Mobility, Privacy/Security, Retail/E-commerce, Robotics/IoT/Hardware, SaaS and Social Impact & Education. TechCrunch is a leading technology media property, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech…

Published

on

FindAir is digitizing asthma therapy with smart inhaler technology.

The TC Top Picks program showcases outstanding early-stage startups across these categories: AI/Machine Learning, Biotech/Healthtech, Blockchain, Fintech, Mobility, Privacy/Security, Retail/E-commerce, Robotics/IoT/Hardware, SaaS and Social Impact & Education.

TechCrunch is a leading technology media property, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech news.

Continue Reading
Advertisement
9 Comments

9 Comments

  1. Abhishek Rao Chimbili

    October 27, 2019 at 4:51 pm

    That is the most useless thing I’ve ever seen.

  2. Brandon S.

    October 27, 2019 at 4:52 pm

    You are supposed to use a spacer. The inhaler alone is not good. Not to mention there are some inhalers that already track the number of uses. This is pointless.

  3. Greg Nulik

    October 27, 2019 at 7:21 pm

    Hope the sensor supports a full dosage.

  4. polyannamoonbeam

    October 27, 2019 at 10:39 pm

    Not enough info …sensor tells you what your trigger was…? How? Blood prick analysis? Heartrate? Allergen analysis? Doctors are now instructed to ration patients to one Ventolin a month, two if you argue at length. There is no science to back up patients self diagnosed need for more, doctors differ on what is sufficient, how to measure severity and are often punitive/ biased against smokers. Many patients become resistant to their Ventolyn due to misuse, long term use.. tracking usage doesnt tell you whether patient needed to use more or less puffs for each event or just misused due to poor technique….severe attacks are not managed by Ventolin. Steroids,adrenalin, intravenous meds, full mask vaporised meds- we use all in winter for son.

  5. Pinitrius

    October 27, 2019 at 11:34 pm

    Being an allergist I was interested to see what this was about… But no! It gives some information about patient adherence to the treatment but as with many products/service it is trying to force a subscription down patients throat without providing real long term value! And the product itself is rendered useless after 12 months due to the non-removable battery!

    To me it is just a gimmick the way they chose to make it and charge for it! Sorry…

  6. TechPimp

    October 28, 2019 at 1:51 am

    I didn’t understand what the heck it does?

  7. Gezaei Teklay

    October 28, 2019 at 2:09 am

    I hope it is helpful for asthma

  8. Arthur

    October 28, 2019 at 9:12 am

    So it counts how many times you use an inhaler a day and displays it on an app?

  9. takeonparis

    October 29, 2019 at 12:15 am

    This is the dumbest interview I’ve ever seen. He doesn’t even bother to ask: “So what does your product DO?” Like what in the actual hell…

Leave a Reply

Cancel reply

Your email address will not be published. Required fields are marked *

People & Blogs

What kind of company is Tesla? | TechCrunch

Tesla unexpectedly gutted its charging team in a new round of layoffs. It begs the question: What kind of company is Tesla, anyway?

Published

on

Tesla unexpectedly gutted its charging team in a new round of layoffs. It begs the question: What kind of company is Tesla, anyway?

Continue Reading

Science & Technology

Inside the ‘cold war’ at Techstars and how AI is accelerating disability tech | Equity Podcast

On this episode of Equity, TechCrunch’s Mary Ann Azevedo, Kirsten Korosec, Dominic-Madori Davis, and Alex Wilhelm break down a deep-dive into the battle at Techstars, Ansa’s latest fundraise, and how AI is accelerating European disability tech startups. Equity is a show about the business of startups, where we unpack the numbers and nuance behind the…

Published

on

On this episode of Equity, TechCrunch’s Mary Ann Azevedo, Kirsten Korosec, Dominic-Madori Davis, and Alex Wilhelm break down a deep-dive into the battle at Techstars, Ansa’s latest fundraise, and how AI is accelerating European disability tech startups.

Equity is a show about the business of startups, where we unpack the numbers and nuance behind the headlines. New episodes drop at 7 a.m. PT every Monday, Wednesday and Friday. Subscribe wherever you get your podcasts.

For episode transcripts and more, head to Simplecast:

Follow Alex Wilhelm on X:
Follow Mary Ann Azevedo on X:
Follow Kirsten Korosec on X:
Follow Dominic-Madori Davis on X:

Check out more from the TechCrunch Podcast Network.
Chain Reaction:
Found:

Follow TechCrunch
YouTube:
Instagram:
TikTok:
X: tcrn.ch/x
Facebook:
Read more:

Continue Reading

People & Blogs

Fourier Intelligence’s Future Therapist Partner Robot | TechCrunch

Will humanoid robots change the future landscape of physical therapy?

Published

on

Will humanoid robots change the future landscape of physical therapy?

Continue Reading

Trending